174 related articles for article (PubMed ID: 24548782)
21. Molecular Diagnostic and Prognostic Subtyping of Gliomas in Tunisian Population.
Trabelsi S; Chabchoub I; Ksira I; Karmeni N; Mama N; Kanoun S; Burford A; Jury A; Mackay A; Popov S; Bouaouina N; Ben Ahmed S; Mokni M; Tlili K; Krifa H; Yacoubi MT; Jones C; Saad A; H'mida Ben Brahim D
Mol Neurobiol; 2017 May; 54(4):2381-2394. PubMed ID: 26957305
[TBL] [Abstract][Full Text] [Related]
22. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
23. H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series.
Lavrador JP; Reisz Z; Sibtain N; Rajwani K; Baig Mirza A; Vergani F; Gullan R; Bhangoo R; Ashkan K; Bleil C; Zebian B; Clark B; Laxton R; King A; Bodi I; Al-Saraj S
Acta Neurochir (Wien); 2023 Jun; 165(6):1615-1633. PubMed ID: 36929449
[TBL] [Abstract][Full Text] [Related]
24. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
25. Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma.
Ross JL; Chen Z; Herting CJ; Grabovska Y; Szulzewsky F; Puigdelloses M; Monterroza L; Switchenko J; Wadhwani NR; Cimino PJ; Mackay A; Jones C; Read RD; MacDonald TJ; Schniederjan M; Becher OJ; Hambardzumyan D
Brain; 2021 Feb; 144(1):53-69. PubMed ID: 33300045
[TBL] [Abstract][Full Text] [Related]
26. High-throughput microRNA profiling of pediatric high-grade gliomas.
Miele E; Buttarelli FR; Arcella A; Begalli F; Garg N; Silvano M; Po A; Baldi C; Carissimo G; Antonelli M; Spinelli GP; Capalbo C; Donofrio V; Morra I; Nozza P; Gulino A; Giangaspero F; Ferretti E
Neuro Oncol; 2014 Jan; 16(2):228-40. PubMed ID: 24305714
[TBL] [Abstract][Full Text] [Related]
27. Distinct genomic aberrations between low-grade and high-grade gliomas of Chinese patients.
Li Y; Wang D; Wang L; Yu J; Du D; Chen Y; Gao P; Wang DM; Yu J; Zhang F; Fu S
PLoS One; 2013; 8(2):e57168. PubMed ID: 23451178
[TBL] [Abstract][Full Text] [Related]
28. Genetic Analysis of Diffuse High-Grade Astrocytomas in Infancy Defines a Novel Molecular Entity.
Gielen GH; Gessi M; Buttarelli FR; Baldi C; Hammes J; zur Muehlen A; Doerner E; Denkhaus D; Warmuth-Metz M; Giangaspero F; Lauriola L; von Bueren AO; Kramm CM; Waha A; Pietsch T
Brain Pathol; 2015 Jul; 25(4):409-17. PubMed ID: 25231549
[TBL] [Abstract][Full Text] [Related]
29. Tumour immune landscape of paediatric high-grade gliomas.
Ross JL; Velazquez Vega J; Plant A; MacDonald TJ; Becher OJ; Hambardzumyan D
Brain; 2021 Oct; 144(9):2594-2609. PubMed ID: 33856022
[TBL] [Abstract][Full Text] [Related]
30. Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas.
Gianno F; Antonelli M; Di Dio T; Minasi S; Donofrio V; Buccoliero AM; Gardiman MP; Pollo B; Diomedi Camassei F; Rossi S; Novello M; Giangaspero F; Arcella A; Gessi M; Buttarelli FR
Am J Surg Pathol; 2021 Feb; 45(2):200-204. PubMed ID: 33428336
[TBL] [Abstract][Full Text] [Related]
31. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis.
Erson-Omay EZ; Çağlayan AO; Schultz N; Weinhold N; Omay SB; Özduman K; Köksal Y; Li J; Serin Harmancı A; Clark V; Carrión-Grant G; Baranoski J; Çağlar C; Barak T; Coşkun S; Baran B; Köse D; Sun J; Bakırcıoğlu M; Moliterno Günel J; Pamir MN; Mishra-Gorur K; Bilguvar K; Yasuno K; Vortmeyer A; Huttner AJ; Sander C; Günel M
Neuro Oncol; 2015 Oct; 17(10):1356-64. PubMed ID: 25740784
[TBL] [Abstract][Full Text] [Related]
32. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
33. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
[TBL] [Abstract][Full Text] [Related]
34. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
36. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
37. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas.
Ryall S; Zapotocky M; Fukuoka K; Nobre L; Guerreiro Stucklin A; Bennett J; Siddaway R; Li C; Pajovic S; Arnoldo A; Kowalski PE; Johnson M; Sheth J; Lassaletta A; Tatevossian RG; Orisme W; Qaddoumi I; Surrey LF; Li MM; Waanders AJ; Gilheeney S; Rosenblum M; Bale T; Tsang DS; Laperriere N; Kulkarni A; Ibrahim GM; Drake J; Dirks P; Taylor MD; Rutka JT; Laughlin S; Shroff M; Shago M; Hazrati LN; D'Arcy C; Ramaswamy V; Bartels U; Huang A; Bouffet E; Karajannis MA; Santi M; Ellison DW; Tabori U; Hawkins C
Cancer Cell; 2020 Apr; 37(4):569-583.e5. PubMed ID: 32289278
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a rare
Deland L; Keane S; Olsson Bontell T; Sjögren H; Fagman H; Øra I; De La Cuesta E; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
Cancer Biol Ther; 2021 Mar; 22(3):184-195. PubMed ID: 33820494
[TBL] [Abstract][Full Text] [Related]
39. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
Sintupisut N; Liu PL; Yeang CH
Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
[TBL] [Abstract][Full Text] [Related]
40. A systematic comparison of copy number alterations in four types of female cancer.
Kaveh F; Baumbusch LO; Nebdal D; Børresen-Dale AL; Lingjærde OC; Edvardsen H; Kristensen VN; Solvang HK
BMC Cancer; 2016 Nov; 16(1):913. PubMed ID: 27876019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
